Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
30 participants
INTERVENTIONAL
2024-11-20
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients with small renal tumours (≤ 7 cm) who meet the other inclusion and exclusion criteria will be asked to have an additional MRI scan at University College London Hospital prior to surgery.
The imaging findings will be compared to the histology result from the removed tumour. In 10 patients the histology will be targeted to a specific location in the tumour based on the imaging. 10 patients will undergo a repeat MRI \<14 d apart to test whether the MRI scans can give the same answer twice (the test repeatability).
The study is expected to run for 24 months and is funded by NIHR.
The chief investigator for the study is Dr Richard Hesketh ([email protected]).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors
NCT02526511
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
NCT06126159
Exploring the Clinical Application Value of CAIX-Targeted PET Imaging in Renal Cancer Patients
NCT06956144
Investigation of Differential Biology of Benign and Malignant Renal Masses Using Advanced Magnetic Resonance Imaging Techniques
NCT06016075
PET/MR Characterization of Renal Cell Carcinomas
NCT04271254
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Histological characterisation of renal tumours
Histological samples of ten patients with tumour histology will be retreived from the Royal Free Hospital Biobank. Slides will be stained using H\&E and CD34 and cell size, stromal space and vascularity will be estimated and used to inform diffusion weighted imaging models.
No interventions assigned to this group
Comparison of microstructural MRI to histology
10 patients with small renal tumours will undergo microstructural MRI. Following MRI the tumours will be surgically resected. The MRI will be co-registered with histology. The degree of correlation between the MRI and underlying histology will be determined.
MRI
Participants undergo an additional MRI scan using novel MRI sequences
Repeatability of MRI of small renal masses
The repeatability of the MRI scan of the small renal mass will be determined by participants undergoing a repeat MRI examination shortly after the first (within 14 d) on the same scanner.
MRI
Participants undergo an additional MRI scan using novel MRI sequences
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
Participants undergo an additional MRI scan using novel MRI sequences
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Confirmed renal tumour ≤ 7 cm planned for surgical resection
3. Willing and able to provide written informed consent
4. Able to lie supine for the duration of an MRI
Exclusion Criteria
2. Contraindication to MR contrast agents
3. Pregnancy
4. Breastfeeding
5. Deranged renal function (eGFR \<30) in the last three months.
6. Previous treatment of the renal tumour e.g., ablation, radiotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Royal Free Hospital NHS Foundation Trust
OTHER
University College London Hospitals
OTHER
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University College London
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
162190
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.